Can you take Duloxetine with Trimethadione?

DULoxetine has a major potential interaction with Bipolar Disorder.

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

DULoxetine has a moderate potential interaction with Bipolar Disorder.

Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.

Trimethadione has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Hematologic toxicities have been associated with the use of oxazolidinedione anticonvulsants. Fatal aplastic anemia, hypoplastic anemia, pancytopenia, agranulocytosis, leukopenia, neutropenia, thrombocytopenia, eosinophilia, retinal and petechial hemorrhages, vaginal bleeding, epistaxis, and bleeding gums have been reported. Therapy with oxazolidinediones should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression. Complete blood counts, including platelets, should be performed in all patients prior to initiating therapy and at monthly intervals, or as often as necessary, thereafter. A moderate degree of neutropenia, with or without a corresponding drop in the leukocyte count, is not uncommon and does not necessitate the discontinuation of therapy. However, more frequent monitoring is recommended if neutrophil count is less than 3000/mm3. Marked depression of blood counts (e.g., neutrophil count < 2500/mm3) is indication for withdrawal of oxazolidinedione therapy. Therapy with oxazolidinediones should ordinarily not be used in patients with severe blood dyscrasias.

DULoxetine has a moderate potential interaction with Dehydration.

Treatment with SNRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

DULoxetine has a major potential interaction with Depression.

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Trimethadione has a moderate potential interaction with Depression.

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

Trimethadione has a major potential interaction with Dermatitis, Drug-Induced.

Potentially serious reactions to oxazolidinedione anticonvulsants such as exfoliative dermatitis and severe forms of erythema multiforme have been reported. Therapy with oxazolidinediones should be administered cautiously in patients with preexisting drug-induced dermatitis, since it may delay the recognition of a potential reaction to oxazolidinediones. Oxazolidinedione therapy should be withdrawn promptly at the first sign of a dermatologic adverse effect. Even a minor acneiform or morbilliform rash should be allowed to clear completely before treatment with these agents is resumed.

DULoxetine has a moderate potential interaction with Diabetes Mellitus.

In clinical trials, treatment with duloxetine delayed-release worsened the glycemic control in some patients with diabetes. Caution should be used when using duloxetine in diabetic patients and their glycemic levels should be checked regularly.

DULoxetine has a moderate potential interaction with Glaucoma, Narrow Angle.

SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.

DULoxetine has a moderate potential interaction with High Blood Pressure.

Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure. Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension. Blood pressure should be assessed prior to initiating treatment and monitored regularly. The dose should be reduced or discontinued if necessary.

DULoxetine has a moderate potential interaction with Hyponatremia.

Treatment with SNRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

DULoxetine has a major potential interaction with Liver Disease.

Postmarketing studies have reported that duloxetine and some other SNRIs like milnacipran may aggravate preexisting liver disease. The use of duloxetine delayed-release and milnacipran should be avoided in patients with chronic liver disease or cirrhosis.

Trimethadione has a major potential interaction with Liver Disease.

Hepatitis has been associated rarely with the use of oxazolidinedione anticonvulsants. In addition, these agents are primarily metabolized by the liver and may accumulate in the presence of liver disease. Therapy with oxazolidinediones should be administered cautiously, if at all, in patients with hepatic impairment. Liver function tests should be performed in all patients prior to initiating therapy and at monthly intervals, or as often as necessary, thereafter. The development of jaundice or other signs of liver dysfunction is indication for withdrawal of oxazolidinedione therapy.

Trimethadione has a moderate potential interaction with Lupus Erythematosus.

Manifestations of systemic lupus erythematosus (SLE) have been associated with the use of oxazolidinedione anticonvulsants. Therapy with oxazolidinediones should be administered cautiously in patients with preexisting SLE. The development or exacerbation of SLE symptoms is indication for withdrawal of oxazolidinedione therapy.

DULoxetine has a moderate potential interaction with Mania.

Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.

Trimethadione has a moderate potential interaction with Myasthenia Gravis.

A myasthenia gravis-like syndrome has been associated with the chronic use of oxazolidinedione anticonvulsants. Therapy with oxazolidinediones should be administered cautiously in patients with myasthenia gravis. The development or exacerbation of myasthenic symptoms is indication for withdrawal of oxazolidinedione therapy.

Trimethadione has a major potential interaction with Optic Nerve Disorder.

Hemeralopia has occurred with the use of oxazolidinedione anticonvulsants, probably as a result of the drugs' effects on the neural layers of the retina. The condition may be reversed by a reduction in dosage. Therapy with oxazolidinediones should be administered cautiously in patients with diseases of the retina or optic nerve. The development of scotomata or other significant ocular abnormality is indication for withdrawal of oxazolidinedione therapy.

Trimethadione has a moderate potential interaction with Psychosis.

Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo. AEDs should be administered cautiously in patients with depression or other psychiatric disorders; phentermine-topiramate should be avoided in patients with history of suicidal attempts or active suicidal ideation. The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior. If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.

DULoxetine has a major potential interaction with Renal Dysfunction.

The use of duloxetine should be avoided in patients with severe renal impairment (GFR <30 mL/min).

Trimethadione has a major potential interaction with Renal Dysfunction.

Fatal nephrosis has been associated with the use of oxazolidinedione anticonvulsants. In addition, the active metabolites of these agents are excreted slowly by the kidney and may accumulate in the presence of renal disease. Therapy with oxazolidinediones should be administered cautiously, if at all, in patients with impaired renal function. Urinalyses should be performed in all patients prior to initiating therapy and at monthly intervals, or as often as necessary, thereafter. The development of persistent or increasing albuminuria or any other significant renal abnormality is indication for withdrawal of oxazolidinedione therapy.

Trimethadione has a major potential interaction with Retinal Disorders.

Hemeralopia has occurred with the use of oxazolidinedione anticonvulsants, probably as a result of the drugs' effects on the neural layers of the retina. The condition may be reversed by a reduction in dosage. Therapy with oxazolidinediones should be administered cautiously in patients with diseases of the retina or optic nerve. The development of scotomata or other significant ocular abnormality is indication for withdrawal of oxazolidinedione therapy.

DULoxetine has a moderate potential interaction with Seizures.

SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.

DULoxetine has a moderate potential interaction with Urinary Tract Infection.

SNRI antidepressants have a noradrenergic effect and can affect urethral resistance. Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.

DULoxetine has a moderate potential interaction with Urinary Tract Obstruction.

SNRI antidepressants have a noradrenergic effect and can affect urethral resistance. Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.